InMed Pharmaceuticals Inc INM

Healthcare Cannabis

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

NDAQ:INM - Post by User

InMed Pharmaceuticals Inc

Bullboard Posts

Comment by Bull4u2on Jun 28, 2017 3:15pm

90 Views

Post# 26415495

RE:IMLFF got millions in funding. Lenders know going .65 easily

Pump it up. Then dump it. It will never get to $0.65. More financings. More dilution.
Need another PR company to make it move. No volume, off another .02 so far today.

hotinfl wrote:
"Each Warrant will have an exercise price of $0.65 per common share and will be exercisable for a period of 24 months following the closing date."

They know what's coming down the pipeline folks! Avg. down before you regret it :)

long play